tetano
Editor, Senior Moderator
Microbes Infect. 2020 Jan 17. pii: S1286-4579(20)30008-3. doi: 10.1016/j.micinf.2019.12.005. [Epub ahead of print] [h=1]Pneumococcal Conjugate Vaccine Modulates Macrophage-mediated Innate Immunity in Pneumonia Caused by Streptococcus pneumoniae Following Influenza.[/h]
Mimura K[SUP]1[/SUP], Kimura S[SUP]2[/SUP], Kajiwara C[SUP]1[/SUP], Nakakubo S[SUP]3[/SUP], Schaller MA[SUP]4[/SUP], Ishii Y[SUP]1[/SUP], Standiford TJ[SUP]5[/SUP], Kunkel SL[SUP]4[/SUP], Tateda K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Pneumococcal conjugate vaccination (PCV) may prevent influenza-related pneumonia, including Streptococcus pneumoniae pneumonia. To investigate PCV efficacy against secondary pneumococcal pneumonia following influenza, PCV was administered intramuscularly 2 and 5 weeks before S. pneumoniae serotype-3 colonization of murine nasopharynges followed by intranasal challenge with a sublethal dose of influenza A virus. Bacterial and viral loads, including innate immune responses were compared across conditions. PCV vaccination improved the survival of mice with secondary pneumococcal pneumonia and significantly reduced the pulmonary bacterial burden. Increased monocyte/macrophage influx into the lungs, alleviated loss of alveolar macrophages and decreased neutrophil influx into the lungs occurred in PCV-treated mice irrespective of pneumococcal colonization. Higher monocyte chemoattractant protein 1 levels and lower levels of CXCL1, interferon-γ, interleukin-17A, and IL-10, were detected in PCV-treated mice. Additionally, PCV treatment activated the macrophage intracellular killing of S. pneumoniae. Collectively, PCV potentially modulates the host's innate immunity and specific antibodies induction. Macrophage-related innate immunity should be further explored to elucidate the efficacy and mechanisms of PCV versus influenza-related life-threatening diseases.
Copyright ? 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
[h=4]KEYWORDS:[/h] MCP-1; Pneumococcal conjugate vaccine; influenza virus infection; innate immunity; monocyte/macrophages; pneumococcal colonization; secondary pneumococcal pneumonia
PMID: 31958572 DOI: 10.1016/j.micinf.2019.12.005
Mimura K[SUP]1[/SUP], Kimura S[SUP]2[/SUP], Kajiwara C[SUP]1[/SUP], Nakakubo S[SUP]3[/SUP], Schaller MA[SUP]4[/SUP], Ishii Y[SUP]1[/SUP], Standiford TJ[SUP]5[/SUP], Kunkel SL[SUP]4[/SUP], Tateda K[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Pneumococcal conjugate vaccination (PCV) may prevent influenza-related pneumonia, including Streptococcus pneumoniae pneumonia. To investigate PCV efficacy against secondary pneumococcal pneumonia following influenza, PCV was administered intramuscularly 2 and 5 weeks before S. pneumoniae serotype-3 colonization of murine nasopharynges followed by intranasal challenge with a sublethal dose of influenza A virus. Bacterial and viral loads, including innate immune responses were compared across conditions. PCV vaccination improved the survival of mice with secondary pneumococcal pneumonia and significantly reduced the pulmonary bacterial burden. Increased monocyte/macrophage influx into the lungs, alleviated loss of alveolar macrophages and decreased neutrophil influx into the lungs occurred in PCV-treated mice irrespective of pneumococcal colonization. Higher monocyte chemoattractant protein 1 levels and lower levels of CXCL1, interferon-γ, interleukin-17A, and IL-10, were detected in PCV-treated mice. Additionally, PCV treatment activated the macrophage intracellular killing of S. pneumoniae. Collectively, PCV potentially modulates the host's innate immunity and specific antibodies induction. Macrophage-related innate immunity should be further explored to elucidate the efficacy and mechanisms of PCV versus influenza-related life-threatening diseases.
Copyright ? 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
[h=4]KEYWORDS:[/h] MCP-1; Pneumococcal conjugate vaccine; influenza virus infection; innate immunity; monocyte/macrophages; pneumococcal colonization; secondary pneumococcal pneumonia
PMID: 31958572 DOI: 10.1016/j.micinf.2019.12.005